RespireRx Pharmaceuticals Inc (RSPI)

[davidal66]

I have a feeling we will see an RD deal, but it will incorporate sleep apnea coupled with resp. depression in tandem. The RD-only companies have not exactly been negotiating with speed; I think that apnea will open things up to larger companies. There is a cost-of-goods argument where CX1739 will need less than three times the dosage of CX717 to produce an effect. Two, why bother with the stigma of CX717. It is an excellent proof of concept molecule for one day testing. Why would any company pursue this? CX1739 does not have this baggage. CX1739 was more than three times as potent for RD in animals than CX1717. What such a deal means is ADHD will have to proceed with another low impact.